Syntermed's NeuroQ™ 3.7 for SPECT Brain Imaging Announced at RSNA

In 2013 Syntermed, Inc. received 510K clearance from the Food and Drug Administration for NeuroQ™ 3.6, software used in nuclear medicine clinics for PET-FDG brain scans plus an additional clearance for its amyloid brain uptake imaging application. As a work in progress, that 510K clearance extends to Syntermed’s newest nuclear medicine software, NeuroQ 3.7 for SPECT brain imaging quantification.

Full Press Release

BrainSPECT.png 2014-7-17-5:46:40

Search By Tags
No tags yet.